MedTrace Logo

Assessing the Utility of Submaximal CPET in Treatment Management of PAH

NCT05977933 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2024-03-13

No results posted yet for this study

Summary

Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality. Moreover, PH disease progression can be rapid; pharmaceutical intervention in early-stage Pulmonary Hypertension (PH) can improve symptoms and functional capacity, and delayed diagnosis and treatment of Pulmonary Hypertension (PH) likely reduces survival.

Conditions

Interventions

DEVICE

Shape II CPET

Submaximal Cardiopulmonary exercise test equipment

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Shape Medical Systems, Inc.

    lead INDUSTRY

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-09-30
Completion
2024-12-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05977933 on ClinicalTrials.gov